Achieve Life Sciences (ACHV) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Achieve Life Sciences (NASDAQ: ACHV):

• 8/19/2026 – Achieve Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/15/2026 – Achieve Life Sciences was downgraded by Wall Street Zen from “hold” to “strong sell”.
• 8/13/2026 – Achieve Life Sciences is now covered by Morgan Stanley. They set an “overweight” rating and a $13.00 price target on the stock.
• 8/12/2026 – Achieve Life Sciences had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $18.00 price target on the stock.
• 8/12/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by UBS Group AG.
• 8/12/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.

Insider Buying and Selling

In other Achieve Life Sciences news, Director Richard Alistair Stewart sold 20,626 shares of Achieve Life Sciences stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the completion of the sale, the director directly owned 208,249 shares of the company’s stock, valued at $1,768,034.01. The trade was a 9.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is owned by company insiders.

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.